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Abstract In neonatal ventricular cardiomyocytes (NVCM),
decreased contractile activity stimulates sarco-endoplasmic
reticulum Ca
2+-ATPase2a (SERCA2a), analogous to re-
duced myocardial load in vivo. This study investigated in
contracting NVCM the role of load-dependent RhoA-
ROCK signaling in SERCA2a regulation. Contractile arrest
of NVCM resulted in low peri-nuclear localized RhoA
levels relative to contracting NVCM. In arrested NVCM,
ROCK activity was decreased (59%) and paralleled a loss
in F-actin levels. Y-27632-induced ROCK inhibition in
contracting NVCM increased SERCA2a messenger RNA
expression by 150%. This stimulation was transcriptional,
as evident from transfections with the SERCA2a promoter.
A reciprocal effect of Y-27632 treatment on the promoter
activity of atrial natriuretic factor was observed. SERCA2a
transcription was not altered by co-transfection of the RhoA-
ROCK-dependent serum response factor (SRF) alone or in
combination with myocardin. Furthermore, GATA4, another
ROCK-dependent transcription factor, induced rather than
repressed SERCA2a transcription. This study shows that
contractile activity suppresses SERCA2a gene expression
via RhoA-ROCK-dependent transcription modulation. This
modulation is likely to be accomplished by a transcription
factor other than SRF, myocardin, or GATA4.
Keywords Transcriptionregulation.Signaltransduction.
RhoA.ROCK.SRF.GATA4.SERCA2a
Introduction
Workload-induced pathological cardiac hypertrophy is
associated with altered expression of a subset of genes.
Particular examples are the increased expression of atrial
natriuretic factor (ANF) and reduced expression of sarco-
plasmic reticulum Ca
2+-ATPase2a (SERCA2a) [9]. The
downregulation of SERCA2a affects calcium handling and
contractile function and may further contribute to the
progression of pathological cardiac hypertrophy. This
inverse regulation of SERCA2a and ANF is observed in
various in vitro studies describing the effect of enhanced
contractile activity [5] or contractile arrest [3]. Moreover, in
vivo unloading of the heart by left ventricular assist devices
( L V A D )h a sa l s ob e e ns h o w nt oi n c r e a s eS E R C A 2 a
expression [2]. The transcriptional control mechanisms of
SERCA2a expression remain largely unexplored.
In a recent in vitro study, we demonstrated that
contractile activity inhibited SERCA2a promoter activity
[31]. The mechanism of this load-induced inhibition is
unclear and is the subject of the current study. One of the
pathways in the load-signaling cascades in cardiac hyper-
trophy involves the small GTPase RhoA [20]. A principal
target of the downstream RhoA effector RhoA-kinase
(ROCK) is the transcription factor serum-response factor
(SRF) [16]. RhoA has been implicated in the signaling
cascades elicited by various hypertrophic stimuli (reviewed
in [4]), including mechanical load [1], and is one of the
mediators of load-induced ANF expression [20]. RhoA has
been shown to be involved in actin dynamics regulation
[19], but its effector ROCK can also directly phosphorylate
proteins involved in excitation–contraction coupling [30].
Furthermore, RhoA-ROCK signaling can alter gene tran-
scription through nuclear translocation of ROCK-dependent
transcription factors, such as SRF [15]. SRF is a 67-kDa
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e-mail: ws.simonides@vumc.nlphosphoprotein that binds to SREs (CC (A/T)6 GG) located
in SRF-responsive promoters [17], including the ANF
promoter [18]. Transcriptional regulation by SRF can be
modified through association with cell-specific co-factors,
like the cardiac-specific factor myocardin [32]. Myocardin
has recently been reported to be upregulated during heart
failure [28]. Involvement of SRF in the regulation of
SERCA2a transcription was indicated by a study by Zhang
et al. [36], in which cardiac-specific overexpression of SRF
induced cardiomyopathy with a concomitant inhibition of
SERCA2a messenger RNA (mRNA) and protein expression.
Taken together, the available evidence points to a role of
the RhoA-ROCK-SRF signaling pathway in mechanical
load-dependent repression of SERCA2a promoter activity.
The aims of the present study were to investigate the
contractile activity-dependent regulation of SERCA2a by
the RhoA-ROCK-SRF signaling pathway in more detail
and compare this with the regulation of the hypertrophy
marker ANF, using an in vitro model of contracting and
quiescent neonatal ventricular cardiomyocytes (NVCM)
[31].
Methods
Cell culture of neonatal rat ventricular cardiomyocytes
All animals were treated according to the national guide-
lines and with the permission of the Institutional Animal
Care and Use Committee (IACUC) of the VU University
Medical Center, The Netherlands. NVCM were isolated
from 2- to 3-day-old Wistar rats (Harlan, Zwijndrecht, The
Netherlands), as previously described [31]. During the
experimental protocol of 3 days, isolated NVCM were
allowed to contract spontaneously (CTR), or were mechan-
ically unloaded, while largely maintaining calcium transi-
ents using the cross-bridge uncoupler 2,3-butanedione
monoxime (BDM; 7.5 mM) [23] (Sigma, Zwijndrecht,
The Netherlands). The role of ROCK signaling in SERCA2a
mRNA expression and promoter activity was investigated
using the ROCK inhibitor Y-27632 (10 μM) [15] (Tocris;
Avonmouth, UK).
Immunohistochemistry
NVCM were washed in phosphate-buffered saline (PBS) at
room temperature and fixed in 2% para-formaldehyde.
Cells were permeabilized in ice-cold acetone/methanol
(30%/70%) and were incubated with a primary rabbit anti-
RhoA antibody (Santa Cruz; 1:100 in PBS+ 1% bovine
serum albumin (BSA)) for 1 h and subsequently incubated
with a cocktail of a secondary swine anti-rabbit antibody
labeled with FITC (DAKO; 1:45 in PBS+ 1% BSA),
together with rhodamine–phalloidin (1:100), to stain for
F-actin filaments. Using fluorescent microscopy, cells were
analyzed for actin filaments and for total RhoA protein
localization.
Western blot analyses
Proteins were separated by SDS polyacrylamide gel
electrophoresis. Gels were blotted onto nitrocellulose
membranes (90 min at 400 mA). Membranes were stained
overnight at 4°C with specific primary antibody against
total α-actin (1:1,000; Sigma), against RhoA (1:1,000;
Cytoskeleton, Denver, USA), or against Thr567-ezrin/
radixin/moesin (ERM; 1:1,000) and total ERM (1:1,000;
both Cell Signaling Technologies, Beverly, USA). The
extent of phosphorylation of ERM was used as a marker of
ROCK activity [19]. Protein expressions were visualized
and quantified using chemiluminiscence (Amersham Bio-
sciences, Freiburg, Germany). Equal protein loadings were
confirmed by Ponceau staining.
Total RNA isolation
Total RNA was isolated from NVCM cultures, using
the Tripure method according to the manufacturer’s
protocol. Total RNA was quantified by A260 measure-
ment and the A260/A280 ratio was used to check for
possible contaminations.
SERCA2a mRNA expression
SERCA2a-specific primers (Invitrogen) were designed
using Primer Express v2.0 to generate amplicons with a
length of 75–125 bp spanning exon–exon junctions
(SERCA2a; F: TTGGCTGTTATGTTGGCGC, R:
AGACTCTCGGACCACCGTCA). Hypoxanthine guanine
phosphoribosyltransferase (HPRT; F: ATGGGAGGCCAT
CACATTGT, R: ATGTAATCCAGCAGGTCAGCAA) was
used as an internal control to normalize gene expressions. A
total of 5 μg of total RNA was used to generate cDNA
strands in a 20-μl reaction volume using the cloned AMV
First Strand Synthesis Kit (Invitrogen). An equivalent of
25 ng total RNAwas subsequently used in the amplification
with 50 nmol/l gene-specific primers and 4 μl SYBR green
master mix (Applied Biosystems) in a total volume of 8 μl,
using standard cycle parameter on an Applied Biosystems
model 7700.
Preparations of plasmids
The rat SERCA2a promoter fragment with 5′-ends at
−6,588 bp (pLuc-S2(6.6)), at −3,263 bp (pLuc-S2(3.2)),
and at −550 bp (pLuc-S2(0.5)) and 3′-ends at +550 bp (+1
786 Pflugers Arch - Eur J Physiol (2009) 458:785–793is the transcription initiation site) were cloned into a
promoterless pGL3-basic Luciferase vector (Promega,
Madison, USA), as described previously [31]. CMV-pRL
(Renilla; Promega) was used for normalization. The plas-
mids expressing full-length SRF (pSRF), full-length myo-
cardin (pMyocardin), and full-length GATA4 (pGATA4)
were generous gifts from Dr. R. Prywes, Dr. Parmacek,
and Dr. M. van Bilsen, respectively. The SRE cis-reporter
construct (pSRE) was obtained from Stratagene (La Jolla,
USA).
Transient transfection assays
Luciferase reporter plasmids driven by either a minimal
promoter containing five tandem repeats of SRE boxes
(pLuc-SRE; 1 μg/10 cm
2), driven by SERCA2a promoter
fragments (250 ng/10 cm
2), were transfected together with
CMV-pRL plasmids (25 ng/10 cm
2) in NVCM using the
Fugene reagent (Roche, Almere). To investigate the role of
SRF and myocardin in SERCA2a promoter regulation,
pSRF and pMyocardin were co-transfected. To investigate
the role of GATA4 in SERCA2a promoter regulation,
pGATA4 (1 μg/10 cm
2) was co-transfected. Empty pOCAT
plasmid was added to the transfection mixtures to equalize
total DNA during transfection. During the transfection
protocol, NVCM were cultured in DMEM containing 0.2%
BSA and 1% P/S. Twenty-four hours after transfection, the
medium was changed and supplemented with blockers
where appropriate. Two days after transfection, cells were
harvested. Promoter activities were determined using the
Dual Luciferase assay kit (Promega).
Statistical analysis
Data are expressed as means ± SEM and were evaluated
using either a Student’s t test or an ANOVAwith Bonferroni
post hoc analysis. Differences were considered significant
at p<0.05.
Results
Effects of contractile arrest on actin-RhoA-ROCK signaling
in cultured cardiac myocytes
Staining of actin filaments showed that 72 h of BDM-
induced contractile arrest while largely maintaining
calcium transients (A. Muller et al., unpublished results;
[23]) resulted in disorganization and loss of actin filaments
(Fig. 1a, b), whereas Western blot analysis showed a
decrease in total actin expression (Fig. 1c). This was
associated with a non-significant reduction (p=0.07) of total
RhoA protein expression (2.8±0.8 a.u. (mean ± SEM of
three experiments) in contracting NVCM vs. 1.0±0.2 a.u.
(mean ± SEM of three experiments) in BDM-arrested
NVCM; Fig. 2c) and a redistribution of RhoA from
sarcomeric, or sarcomere-associated structures [29], to peri-
nuclear regions (Fig. 2a, b). ROCK activity was reduced in
these cultures, as evident from a decreased ratio of
phosphorylated to total ERM relative to contracting NVCM
(Fig. 2d).
Effects of ROCK inhibition on SERCA2a mRNA
expression
To investigate the role of ROCK in contractile activity-
dependent regulation of SERCA2a mRNA expression, the
level of SERCA2a mRNAwas determined in RNA isolated
from contracting NVCM that were either untreated or were
treated with the selective ROCK-blocker Y-27632 (10 µM)
[15] .B a s e do nv i s u a li n s p e c t i o n ,3d a y so fY - 2 7 6 3 2
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Fig. 1 Effects of contractile arrest on actin expression and distribu-
tion. a, b Actin sarcomere organization in contracting NVCM (a) and
in contraction-arrested NVCM (b) as determined by immunohisto-
chemistry. c Total actin protein expression is decreased in contraction-
arrested NVCM (BDM) compared to contracting NVCM (CTR)a s
determined by Western blot analysis. Data are means ± SEM of at
least three independent experiments. †p<0.05. CTR contracting
NVCM, BDM contraction-arrested NVCM (7.5 mM 2,3-butanedione
monoxime for 72 h)
Pflugers Arch - Eur J Physiol (2009) 458:785–793 787spontaneously contracting NVCM, i.e., (89±42 vs. 118±
49 beats per minute, respectively; means ± SEM of four
experiments). Furthermore, rhodamine-conjugated phalloidin
staining of actin filaments was comparable in control
contracting NVCM and Y-27632-treated NVCM, indicating
comparable contractile ability (Fig. 3a ) .H o w e v e r ,e f f e c t so f
Y-27632 treatment on cell shortening and calcium transients
cannot be excluded.
Three days of exposure to Y-27632 resulted in a significant
150% increase in SERCA2a mRNA expression (Fig. 3b)
without affecting ANF mRNA expression (Fig. 3c). The
increase in SERCA2a mRNA levels in BDM-treated cultures
was similar to the increase in Y-27632-treated cultures (2.5±
0.1 (n=5) and 2.5±0.6 (n=4), respectively; means ± SEM).
ROCK signaling and SERCA2a transcription regulation
Next, we investigated whether transcriptional mechanisms
underlie the ROCK-induced changes in SERCA2a mRNA
expression. Contracting NVCM were transiently transfected
with luciferase-reporter plasmids driven by SERCA2a
promoter fragments of different lengths (0.55, 3.3, and
6.6 kb, respectively). Treatment with Y-27632 did not affect
the activity of the 0.55 and 3.3 kb SERCA2a promoter
fragment, but increased the transcriptional activity of the
6.6-kb SERCA2a promoter fragment by 80% (Fig. 4a, b).
Treatment with Y-27632 significantly decreased ANF
promoter activity (−41%; Fig. 4d).
Effects of contractile arrest and ROCK inhibition on SRF
activity
To monitor the changes in activity of the ROCK-dependent
transcription factor SRF induced by contractile arrest and
ROCK inhibition, transfection experiments were performed
in NVCM, using a luciferase reporter construct driven by a
promoter containing multiple serum response elements
(pLuc-SRE). In these experiments, stimulation of the
activity of the SRE-containing promoter by an SRF
expression plasmid (pSRF) was used as a positive control
(2.2-fold increase; Fig. 5a). Spontaneously contracting
NVCM, cultured with or without the ROCK inhibitor Y-
27632, and contraction-arrested NVCM were transiently
transfected with pLuc-SRE. The activity of the SRE-
containing promoter was lower in spontaneously contract-
ing NVCM treated with the ROCK inhibitor Y-27632
(−25%) and in contraction-arrested NVCM (−75%), com-
pared to untreated NVCM (Fig. 5a). This indicates that
ROCK is involved in contractile activity-mediated SRF
activation.
SERCA2a transcription regulation by SRF
The role of SRF in regulating SERCA2a gene transcription
is unexplored. To investigate whether SRF is a candidate
mediator of the ROCK-dependent decrease of SERCA2a
promoter activity, co-transfection studies were performed in
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Fig. 2 Effectsofcontractilearrest
on RhoA-ROCK signaling. a, b
Redistribution of RhoA from sar-
comeric or sarcomere-associated
structures in contracting NVCM
(a; arrows) to peri-nuclear
regions in contraction-arrested
NVCM (b; arrows). c Total
RhoA protein expression is
reduced by 64% in contraction-
arrested NVCM relative to con-
tracting NVCM, as determined
by Western blot analysis (not
significant, p=0.07). d Contrac-
tile arrest reduces phosphoryla-
tion of ezrin/radixin/moesin
(ERM), a marker for ROCK
activity. The ratio of phosphory-
lated Thr567 ERM (pERM)t o
total ERM was determined by
Western blot analysis. Data are
means ± SEM of at least three
independent experiments. CTR
spontaneously contracting
NVCM, BDM contraction-
arrested NVCM (7.5 mM 2,3-
butanedione monoxime for 72 h).
†p<0.05 vs. CTR
788 Pflugers Arch - Eur J Physiol (2009) 458:785–793NVCM using the pLuc-S2(6.6) reporter construct and an
SRF expression plasmid (pSRF). pSRF was transfected at
an input of 100 pg plasmid/10 cm
2 [22, 37]. Transfection of
pSRF did not result in alteration of SERCA2a promoter
activity. Myocardin was subsequently tested as a potential
co-factor required for the repression of promoter activity.
However, co-transfection of a myocardin expression vector
(pMyocardin; 100 pg/10 cm
2) was without effect (Fig. 5b).
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Fig. 4 Effects of ROCK inhibi-
tion by Y-27632 on SERCA2a
and ANF promoter activity.
Contracting NVCM were trans-
fected with promoter-luciferase
(Luc) reporter plasmids driven
by 0.55 kb (a), 3.3 kb (b), or
6.6 kb (c) of the SERCA2a
promoter sequence or 638 bp of
the ANF promoter sequence (d).
The CMV-Renilla (Ren) plasmid
was co-transfected for normali-
zation of the luciferase expres-
sion. Y-27632 treatment did not
affect the activity of the 0.55 or
3.3 kb SERCA2a promoter
fragment (a, b), but stimulated
the activity of the 6.6-kb
SERCA2a promoter fragment
(c), whereas ANF promoter ac-
tivity was repressed (d). Data
are presented as means ± SEM
of six independent experiments.
CTR spontaneously contracting
NVCM, Y-27632 contracting
NVCM treated with 10 µM Y-
27632 (treatment did not affect
contractile activity). *p<0.001
vs. CTR
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Fig. 3 Rhodamine-conjugated
phalloidin staining of actin fila-
ments in control contracting
NVCM (CTR) and Y-27632-
treated NVCM (Y-27632), indica-
ting comparable contractile ability
(see also “Effects of ROCK
inhibition on SERCA2a mRNA
expression” in the Results section;
a). Effects of ROCK inhibition
on SERCA2a and ANF mRNA
expression (b, c). SERCA2a
mRNA level was stimulated by
Y-27632-treatment (b), whereas
ANF mRNA level was unchanged
(c). Hypoxanthine guanine phos-
phoribosyltransferase (HPRT)w a s
used as an internal control to
normalize SERCA2a and ANF
mRNA expression. Data are pre-
sented as means ± SEM of four
independent experiments. CTR
spontaneously contracting NVCM,
Y-27632 contracting NVCM
treated with 10 µM Y-27632.
†p<0.05 vs. CTR
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implicated in hypertrophy and is also increased by RhoA-
ROCK signaling. GATA4 is therefore a potential mediator
of the ROCK-dependent decrease of SERCA2a promoter
activity. However, the data in Fig. 5b show that GATA4 is
an activator of SERCA2a promoter activity rather than a
repressor.
Discussion
Contractile activity of NVCM has previously been demon-
strated to decrease SERCA2a mRNA expression. The
present study provides evidence for an inhibitory role of
contraction-induced RhoA-ROCK signaling in the regula-
tion of SERCA2a gene transcription and mRNA expression.
Development of maladaptive myocardial hypertrophy as
a result of hemodynamic overload is associated with
upregulation of ANF mRNA expression and downregulation
of SERCA2a mRNA expression [9]. Maladaptive myocar-
dial hypertrophy and unfavorable LV remodeling can result
from enhanced RhoA signaling [14, 24], which is associ-
ated with altered myofibrillar organization [12, 33]. In a
variety of experiments using pro-hypertrophic stimuli such
as lysophosphatidic acid [11], phenylephrine [34], and
mechanical stress [20], enhanced RhoA signaling has been
demonstrated to result in upregulation of ANF mRNA
expression.
Although the role of RhoA signaling in the regulation of
ANF mRNA expression and transcription is well estab-
lished [12, 27], its role in SERCA2a promoter regulation
remains to be elucidated. In contraction-arrested NVCM,
SERCA2a mRNA expression was recently demonstrated
to depend on the upregulation of SERCA2a promoter
activity by a synergistic action of NFATc4 and MEF2c, the
downstream transcription factors of the calcium-dependent
calcineurin and CAMK-II pathways, respectively [31]. In this
model, contractile activity suppressed SERCA2a mRNA
expression by a mechanism that was apparently independent
of the calcineurin signaling pathway since nuclear transloca-
tion of NFAT was similar in spontaneously contracting and
arrested NVCM. It remained unclear, however, whether
altered SERCA2a promoter activities underlie the observed
load-dependent changes in mRNA expression levels, and
which signaling pathways are involved. The current study
shows RhoA-ROCK signaling to be involved in the down-
regulation of SERCA2a promoter activity as a result of
contractile activityofNVCM.Incontraction-arrestedNVCM,
redistribution of RhoA to peri-nuclear levels paralleled a loss
in F-actin structures and coincided with low activity of the
RhoA-target protein ROCK. Inhibition of ROCK in contract-
ing NVCM increased SERCA2a mRNA at the level of gene
transcription, but the RhoA-ROCK-dependent transcription
factors SRF, myocardin, and GATA4 appeared not to be
involved in the repression of SERCA2a transcription. The
contractile activity-dependent decrease of SERCA2a tran-
scription is likely to be accomplished by an as yet unknown
RhoA-ROCK-dependent transcription factor.
Effects of contractile arrest on RhoA-ROCK signaling
Following 3 days of contractile arrest, the cultured NVCM
exhibited disorganization of the cytoskeleton with a
concomitant decreased expression of actin, as evident from
the rhodamine–phalloidin staining of the actin filaments
and from Western blot analysis, respectively. Since RhoA-
ROCK signaling is closely linked to actin organization,
the previously observed contractile arrest-induced increase
in SERCA2a mRNA expression [31] could have resulted
from suppression of RhoA-ROCK signaling because of
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Fig. 5 SRE activity is decreased by contractile arrest and ROCK
inhibition and stimulated by SRF (a). Direct effects of SRF alone or in
combination with its co-factor myocardin on SERCA2a promoter
activity were not found. GATA4 increased SERCA2a promoter
activity (b). Data are presented as means ± SEM of at least five
independent experiments. CTR contracting NVCM, Y-27632 contract-
ing NVCM treated with 10 µM Y-27632, BDM contraction-arrested
NVCM (7.5 mM 2,3-butanedione monoxime for 72 h); ***p<0.05 vs.
CTR, **p<0.001 vs. CTR, *p<0.001 vs. CTR
790 Pflugers Arch - Eur J Physiol (2009) 458:785–793cytoskeletal disorganization. The decrease in total RhoA
expression, its altered distribution to more peri-nuclear
regions,andtheobserveddecreasedactivityofitssubstrate,
ROCK, strongly suggest that unloading results in impaired
RhoA-ROCK signaling.
Role of ROCK signaling SERCA2a transcription regulation
Selective ROCK inhibition by Y-27632 in contracting
NVCM resulted in upregulation of SERCA2a promoter
activity, which was accompanied by downregulation of
ANF promoter activity. This ability of ROCK to induce
reciprocal changes in SERCA2a and ANF gene transcrip-
tion confirms an earlier report which showed that decreased
Rho kinase activity blunts pathological myocardial hyper-
trophy in a model of hypertension-induced heart failure
[25].
Examination of various lengths of the SERCA2a
promoter revealed that only the activity of the 6.6-kb
fragment, not of the 0.55- or 3.3-kb fragment, was
increased by ROCK inhibition. This suggests that RhoA-
ROCK-sensitive regions are located in the far-upstream
regions of the promoter. The increased activity of the 6.6-kb
SERCA2a promoter in ROCK-inhibited NVCM corre-
sponded with an increased SERCA2a mRNA expression,
suggesting that the far-upstream region of the SERCA2a
promoter is of physiological significance. The previously
reported increase of SERCA2a promoter activity by the Ca
2+
signaling-dependent transcription factors NFAT and MEF2
[31] also involved the far-upstream region of the SERCA2a
promoter. The present study suggests that the effect of these
stimulatory transcription factors is counteracted by inhibi-
tory mechanical load-induced RhoA-ROCK-dependent
transcription factors. Although SERCA2a promoter activity
was modulated to a larger extent by NFAT and MEF
compared to the ROCK-dependent regulation (a 3.5-fold
increase induced by NFAT/MEF2 compared to a 1.75-fold
increase by ROCK inhibition), we cannot draw conclusions
concerning the relative importance of these pathways due to
the differences in experimental setup. In the NFAT/MEF2
transfection experiments, co-transfection with NFAT/MEF
expression plasmids provided saturating levels of these
transcription factors, while the effect of ROCK inhibition
by Y-27632 treatment on SERCA2a promoter activity was
dependent on endogenous levels of transcription factors,
which may have been limiting.
Analysis of the expression of an SRE-driven reporter
gene in contracting NVCM showed that SRF is a
contraction- and ROCK-sensitive transcription factor. The
observed large difference in SRF activity between Y-27632-
treated cells and BDM-treated cells (reduction of 25% and
75%, respectively, as compared to control cultures) may
result from activation of load-dependent pathways that
activate SRF, other than the RhoA-ROCK pathway, that
remain active in the still contracting Y-27632-treated cells
but are abolished in the contraction-arrested BDM-treated
cells. A candidate is the load-dependent TGFβ-activated
kinase pathway, which has been shown to stimulate SRE
activity [35].
The present study shows that SERCA2a promoter
activity is not repressed by SRF alone, or in combination
with its co-factor myocardin, suggesting that another
RhoA-ROCK-dependent transcription factor is involved in
the observed contractile activity-dependent repression of
SERCA2a expression.
The transcription factor GATA4 was considered to be a
likely candidate. It has been described that RhoA-ROCK
signaling participates in GATA4-dependent effects of
hypertrophic neurohumoral factors via the ERK [34]o r
p38-MAPKK pathway [6] in NVCM. Furthermore, it was
shown that GATA4 is a mediator of stretch-induced
cardiomyocyte hypertrophy [21]. Taken together, these data
indicate that GATA4 is a potential mediator of RhoA-
ROCK-induced decrease of SERCA2a transcription. This
study shows that GATA4 stimulated SERCA2a promoter
activity, which is opposite to the expected inhibition if
GATA4 were the downstream transcription factor of the
ROCK signaling cascade regulating SERCA2a expression.
These results appear to exclude not only SRF, but also
GATA4 as ROCK-dependent transcription factors mediat-
ing the load-dependent inhibition of SERCA2a expression
in this model.
Study limitations
The use of BDM as a cross-bridge uncoupler in our
experimental setup allows the dissection of calcium-
dependent and load-dependent effects of contractile
activity, which is not possible in in vivo models of cardiac
hypertrophy. A restriction of the use of the chemical
phosphatase BDM is that it may influence the activity of
proteins other than myosin ATPase, like the L-type
calcium channel and gap junction channels [7, 8, 26].
However, these effects were observed at higher concen-
trations of BDM (between 15-50 mM) than those required
to inhibit contractile activity in the present study (7.5 mM).
Although calcium transients are largely maintained in the
presence of 7.5 mM BDM (A. Muller et al, unpublished
results; [23]), it cannot be excluded that changes in
calcium transients influenced the effects observed upon
BDM-treatment and therefore cannot be fully ascribed to
changes in mechanical load. Similarly, changes in calcium
transients due to Y-27632 treatment cannot be excluded.
A limitation of the experimental setup used in this in
vitro study is that a condition of complete absence of
mechanical load is compared to a condition of mechanical
Pflugers Arch - Eur J Physiol (2009) 458:785–793 791load imposed by spontaneous contractions, whereas cardiac
hypertrophy in vivo develops in response to a sustained
increase in mechanical load of contracting myocytes. Despite
this limitation of the model of contractile arrest induced by
BDM treatment, the model may be used to elucidate basic
mechanical load-dependent regulatory mechanisms. Cadre
et al. [5] showed that stretching of NVCM induced a
decrease of SERCA2a expression, which indicates that
there is a resemblance between mechanical load resulting
from spontaneous contractions and the mechanical load
resulting from mechanical deformation by stretch. Fur-
thermore, a recent study by Jacot et al. [13]s h o w e dt h a t
NVCM that were grown on substrates with variable stiffness,
a very stiff substrate, resulted in decreased SERCA2a mRNA
expression, which was suggested to involve RhoA-ROCK
signaling.
An in vivo condition that may resemble to some extent
our in vitro unloading approach is the use of human LVAD.
During end-stage heart failure, patients receive LVAD to
reduce hemodynamic overload in order to bridge the period
preceding cardiac transplantation. LVAD treatment im-
proved cardiac function by inducing a process called reverse
remodeling, with improved cardiac relaxation and increased
expression levels of calcium handling proteins including
SERCA2a [10].
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